Centralised procedure variations: the source map for MAHs

Separate classification from procedure

The Variations Regulation and Classification Guideline establish the legal and classification framework. EMA post-authorisation guidance then explains how centrally authorised products are handled operationally, including Type IA, Type IB, Type II, grouping, worksharing and extensions.

A procedure plan should cite both levels. An EMA operational instruction does not replace the legal classification source, and a classification code alone does not answer every submission question.

The Variations Regulation was amended by Delegated Regulation (EU) 2024/1701, applicable from 1 January 2025, and the new Commission classification guidelines (C/2025/5045) apply from 15 January 2026. Internal SOPs and templates written against the earlier framework should be re-checked before they are relied on.

Who assesses a centralised variation

EMA handles Type IA and Type IB notifications for centrally authorised products. Type II variations are assessed by the CHMP through the rapporteur appointed for the product, with PRAC involvement where the change concerns pharmacovigilance or the risk management plan. The committee opinion goes to the European Commission, which updates the marketing authorisation decision where the change requires it.

Extensions are not variations in the procedural sense. The Variations Regulation requires an extension to be assessed under the same procedure as the initial marketing authorisation, which means a full CHMP timetable and not a Type II one.

Contact the EMA product team early for anything unusual: a change that does not fit the guideline, a complex group, or a worksharing procedure spanning centrally and nationally authorised products. A pre-submission question costs less time than a validation issue.

Timetables and what they depend on

Type IA changes are implemented first and notified afterwards: within twelve months as an annual update, grouping or super-grouping, or immediately where the guideline entry requires it. Type IB notifications are deemed favourable if EMA sends no unfavourable opinion within 30 days of acknowledging a valid notification; after an unfavourable opinion the holder has 30 days to submit an amended one.

For Type II variations EMA issues an opinion within 60 days of a valid application. The period can be shortened for urgent matters or extended to 90 days for changes to therapeutic indications and for groups combined by agreement, and requests for supplementary information suspend the clock. In practice, start dates follow EMA's published procedural timetables, so working back from the target committee meeting to the matching submission deadline is the first step of any realistic plan.

The Commission decision follows the opinion. The Commission amends the decision within two months for a defined list of changes — new or modified therapeutic indications, new contraindications, posology changes, certain vaccine strain or antigen changes, and other Type II changes EMA identifies as a significant public health concern — and within twelve months for everything else. Check which applies before telling commercial teams when updated product information takes legal effect.

• Pick the CHMP timetable before fixing the internal authoring plan.
• Plan resources for at least one request for supplementary information on every Type II.
• Confirm whether the outcome falls in the two-month or twelve-month Commission decision track.
• Record implementation dates for Type IA changes as they occur.

Check the current EMA operating route

EMA states that MAHs should use IRIS to manage variations and extensions after the original submission, while the submission gateway continues to serve a different function. Confirm the current EMA instructions, forms and product-specific contacts before dispatch.

The eCTD sequence is delivered through the eSubmission Gateway or Web Client, and the application form is the EU electronic application form. Procedure data in IRIS, the application form and the eCTD envelope must describe the same procedure; mismatches between them are a routine validation finding.

• Confirm the variation category, scope and affected marketing authorisations.
• Check whether grouping or mandatory worksharing applies.
• Reconcile application data, IRIS procedure data and the eCTD sequence.
• Include updated product information, translations and supporting summaries where required.
• Record the EMA guidance revision and access date in the submission plan.

Grouping and worksharing with national products

Grouping combines several changes to one marketing authorisation in a single submission. Combinations listed in Annex III of the Variations Regulation can be grouped as of right; others need EMA's agreement. Type IA changes can also be super-grouped into one notification across several authorisations of the same holder, in the cases the classification guidelines list.

Worksharing assesses the same Type IB or Type II change, or group without an extension, once for several authorisations of the same holder. When at least one of those authorisations is centrally authorised, EMA is the reference authority, including for the national or MRP authorisations in the procedure. That makes worksharing the practical route for aligning a centrally authorised product with other authorisations of the same substance.

A worksharing request can be refused where each product would need its own supporting data or a product-specific assessment. The worksharing Q&A on the EMA site sets out what EMA expects with the request; read it before committing to a worksharing plan.

Product information and linguistic review

Changes to the SmPC, labelling or package leaflet use the current QRD templates and are submitted in English during assessment. After a positive opinion, translations into all EU languages, plus Icelandic and Norwegian, go through EMA's post-opinion linguistic review with Member State comments on short, fixed deadlines.

Prepare translations while the assessment is running. The linguistic review timeline leaves no room to commission them after the opinion, and a late or poor translation delays the Commission decision for every language.

National particulars printed on the outer packaging — the 'blue box' — are defined per Member State and are not part of the harmonised annexes. Check them separately when a labelling change is made.

Obligations that run alongside the variation

EMA fees for post-authorisation procedures are set by Regulation (EU) 2024/568, which applies from 1 January 2025. Use the current fee rules and explanatory note rather than a legacy fee table, since the structure changed with that regulation.

Product data held in the Article 57 database must be kept current. When a variation changes information recorded there, the holder has to update the entry within the deadline EMA specifies, and the obligation is easy to miss because it sits outside the variation procedure itself.

Post-authorisation measures and safety procedures often feed variations. Outcomes of a PSUR single assessment or a referral may need to be implemented through a variation, and results from post-authorisation measures that affect the product information are submitted as variations rather than as standalone reports.

• Check the fee applicable under Regulation (EU) 2024/568 before dispatch.
• Schedule the Article 57 database update when the variation is approved.
• Link variations that implement PSUSA, referral or post-authorisation measure outcomes to that procedure.

Keep sources current at the point of use

EMA post-authorisation pages and consolidated procedural advice are updated regularly. Use the live topic page as the entry point, then verify that downloaded documents and internal SOPs match its latest revision.

Qualified review remains necessary for the product facts, regulatory strategy, classification and final application content.